The study demonstrates that T cell activation increases intracellular trafficking via the endoplasmic-reticulum-to-Golgi pathway, and that a protein known as SEC23B — a subunit of the COPII complex — regulates T cells’ production of these important secretory proteins after activation. The work points toward a new potential therapeutic target for decreasing the severity of graft-versus-host-disease (GVHD), a potentially fatal complication of bone marrow transplantation.
A study aimed at better understanding why some critically ill patients develop multidrug-resistant infections is underway by researchers at The University of Texas Health Science Center at Houston (UTHealth). The multi-institution study will enroll patients at Memorial Hermann Hospital-Texas Medical Center and The University of Texas MD Anderson Cancer Center.
Roswell Park Study: Delaying Antiviral Treatment May Boost Immunity in Stem Cell Transplant Recipients
Patients who develop cytomegalovirus infections after allogeneic stem cell transplantation may be able to develop an immunity against the virus, strengthen their immune system and reduce reliance on strong antiviral medications, a team from Roswell Park reports in the journal Biology of Blood and Marrow Transplantation.
Memorial Sloan Kettering – Hackensack Meridian Health Partnership Announces Funding for Inaugural Immunology Research Collaboration Projects
The Memorial Sloan Kettering – Hackensack Meridian Health Partnership has formed an Immunology Research Collaboration, through which researchers can apply for funding to support innovative investigations to explore the power of the immune system and ways it may be harnessed to fight cancer. Three researchers’ projects were selected in 2020 for funding support.
Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.
Granulocyte colony-stimulating factor (GCSF) is currently used to treat neutropenia due to chemotherapy and has been successfully used for patients who require bone marrow transplants. The study is the first to report on the neuroprotective effect of GCSF in vivo and showed that it improved neurological deficits that occur in the first few days following cerebral ischemia. GCSF improved long-term behavioral outcomes while also stimulating a neural progenitor recovery response in a mouse model.
A new study from Washington University School of Medicine in St. Louis suggests that extremely rare, harmful genetic mutations present in healthy donors’ stem cells — though not causing health problems in the donors — may be passed on to cancer patients receiving stem cell transplants, potentially creating health problems for the recipients. Among the concerns are heart damage, graft-versus-host disease and possible new leukemias.
New NCCN Guidelines Debut to Manage Complications and Improve Readiness for Stem Cell Transplant Recipients
The National Comprehensive Cancer Network (NCCN) published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Hematopoietic Cell Transplantation, (aka stem cell transplant or bone marrow transplant), with step-by-step information on best practices for this blood cancer treatment